What question did this study set out to answer?

To compare the safety and effectiveness of CAR‐T cell therapy versus chemotherapy before allo‐HSCT in B‐ALL patients.

January 23, 2026European Journal Of Haematology

Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival

View Full Paper

Ask AI

Bookmark

Authors

NWNing WuPeking University JKJun KongPeking University MLMeng LvPeking University

Discussion

Member takes

Implication

This comparison reports treatment complications and survival rates in B‐ALL patients undergoing allo‐HSCT after CAR‐T therapy or chemotherapy, suggesting similar outcomes.

Key Points

To compare the safety and effectiveness of CAR‐T cell therapy versus chemotherapy before allo‐HSCT in B‐ALL patients.
Analyzed outcomes of 443 B‐ALL patients
Compared results between 50 CAR‐T and 393 chemotherapy patients
Conducted a median follow-up of 30 months
The CAR‐T group had lower chronic graft‐versus‐host disease incidence (30.9% vs. 44.0%)
Higher veno‐occlusive disease incidence in CAR‐T group (4% vs. 0.5%)
Overall survival rates were comparable (90.9% vs. 94.6%)
Non‐relapse mortality higher in CAR‐T group (10.9% vs. 4.3%)
Leukemia‐free survival lower in CAR‐T group (80.0% vs. 86.8%)

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69730fc4c8125b09b0d1f8d6 https://doi.org/10.1111/ejh.70108

View Full Paper

Ask AI

Bookmark

January 23, 2026European Journal Of Haematology

Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ HSCT in B‐ ALL : A Comparison of Treatment Complications and Survival

View Full Paper

Ask AI

Bookmark

Authors

NWNing WuPeking University JKJun KongPeking University MLMeng LvPeking University

Discussion

Member takes

Implication

This comparison reports treatment complications and survival rates in B‐ALL patients undergoing allo‐HSCT after CAR‐T therapy or chemotherapy, suggesting similar outcomes.

Key Points

To compare the safety and effectiveness of CAR‐T cell therapy versus chemotherapy before allo‐HSCT in B‐ALL patients.
Analyzed outcomes of 443 B‐ALL patients
Compared results between 50 CAR‐T and 393 chemotherapy patients
Conducted a median follow-up of 30 months
The CAR‐T group had lower chronic graft‐versus‐host disease incidence (30.9% vs. 44.0%)
Higher veno‐occlusive disease incidence in CAR‐T group (4% vs. 0.5%)
Overall survival rates were comparable (90.9% vs. 94.6%)
Non‐relapse mortality higher in CAR‐T group (10.9% vs. 4.3%)
Leukemia‐free survival lower in CAR‐T group (80.0% vs. 86.8%)

Cite This Study

Wu et al. (2026) studied this question.

synapsesocial.com/papers/69730fc4c8125b09b0d1f8d6 https://doi.org/10.1111/ejh.70108

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark